Jan Baughman

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Yung‐Jue Bang, Giuseppe Giaccone, S.-A. Im et al. · Annals of Oncology · 2017 · 225 citations · Full text

Medicine, Oncology, Pharmacology +16

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Charu Aggarwal, Amy Prawira, Scott Antonia et al. · Journal for ImmunoTherapy of Cancer · 2022 · 141 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy of computerized decision support for mechanical ventilation: results of a prospective multi-center randomized trial.

Thomas D. East, L K Heermann, R L Bradshaw et al. · PubMed · 1999 · 117 citations

Computing, Health Informatics, Clinical Decision Support +16

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

John D. Powderly, Gregory M. Coté, Keith T. Flaherty et al. · Journal for ImmunoTherapy of Cancer · 2015 · 102 citations · Full text

Pharmacy, Hematology, Oncology +14

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, John E. Godwin, Michael P. Rettig et al. · Blood · 2017 · 62 citations

Medicine, Hematology, Oncology +17